Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies

被引：36

作者：

MacDonald, Isaiah ^{[1
]}

Nixon, Nancy A. ^{[2
]}

Khan, Omar F. ^{[2
]}

机构：

[1] Univ Alberta, Fac Med & Dent, Edmonton, AB T6G 2R7, Canada

[2] Univ Calgary, Dept Oncol, Calgary, AB T2N 4N2, Canada

来源：

CURRENT ONCOLOGY | 2022年 / 29卷 / 07期

关键词：

breast cancer; triple negative; adjuvant; neoadjuvant; curative intent; chemotherapy; immunotherapy; PARPi; STANDARD NEOADJUVANT CHEMOTHERAPY; ADJUVANT CAPECITABINE; CARBOPLATIN; VELIPARIB; BRIGHTNESS; SURVIVAL; TRIAL;

D O I：

10.3390/curroncol29070378

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer is the most commonly diagnosed malignancy in women, with triple-negative breast cancer (TNBC) accounting for 10-20% of cases. Historically, fewer treatment options have existed for this subtype of breast cancer, with cytotoxic chemotherapy playing a predominant role. This article aims to review the current treatment paradigm for curative-intent TNBC, while also reviewing potential future developments in this landscape. In addition to chemotherapy, recent advances in the understanding of the molecular biology of TNBC have led to promising new studies of targeted and immune checkpoint inhibitor therapies in the curative-intent setting. The appropriate selection of TNBC patient subgroups with a higher likelihood of benefit from treatment is critical to identify the best treatment approach.

引用

页码：4768 / 4778

页数：11

共 49 条

[1] Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies [J].

Abuhadra, Nour ;

Stecklein, Shane ;

Sharma, Priyanka ;

Moulder, Stacy .

ONCOLOGIST, 2022, 27 (01) :30-39

[2] Homologous recombination deficiency in breast cancer: Implications for risk, cancer development, and therapy [J].

Ali, Rayhaan M. M. ;

McIntosh, Stuart A. ;

Savage, Kienan I. .

GENES CHROMOSOMES & CANCER, 2021, 60 (05) :358-372

[3]

[Anonymous], 2010, Doxorubicin Hydrochloride Injection Label - FDA

[4]

[Anonymous], EFFICACY SAFETY COMP

[5] Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Mayer, I. A. ;

Vahdat, L. T. ;

Tolaney, S. M. ;

Isakoff, S. J. ;

Diamond, J. R. ;

O'Shaughnessy, J. ;

Moroose, R. L. ;

Santin, A. D. ;

Abramson, V. G. ;

Shah, N. C. ;

Rugo, H. S. ;

Goldenberg, D. M. ;

Sweidan, A. M. ;

Iannone, R. ;

Washkowitz, S. ;

Sharkey, R. M. ;

Wegener, W. A. ;

Kalinsky, K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08) :741-751

[6] Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology) [J].

Blum, Joanne L. ;

Flynn, Patrick J. ;

Yothers, Greg ;

Asmar, Lina ;

Geyer, Charles E., Jr. ;

Jacobs, Samuel A. ;

Robert, Nicholas J. ;

Hopkins, Judith O. ;

O'Shaughnessy, Joyce A. ;

Dang, Chau T. ;

Gomez, Henry Leonidas ;

Fehrenbacher, Louis ;

Vukelja, Svetislava J. ;

Lyss, Alan P. ;

Paul, Devchand ;

Brufsky, Adam M. ;

Jeong, Jong-Hyeon ;

Colangelo, Linda H. ;

Swain, Sandra M. ;

Mamounas, Eleftherios P. ;

Jones, Stephen E. ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) :2647-+

[7] Projected estimates of cancer in Canada in 2022 [J].

Brenner, Darren R. ;

Poirier, Abbey ;

Woods, Ryan R. ;

Ellison, Larry F. ;

Billette, Jean-Michel ;

Demers, Alain A. ;

Zhang, Shary Xinyu ;

Yao, Chunhe ;

Finley, Christian ;

Fitzgerald, Natalie ;

Saint-Jacques, Nathalie ;

Shack, Lorraine ;

Turner, Donna ;

Holmes, Elizabeth .

CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (17) :E601-E607

[8] The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes [J].

Carey, Lisa A. ;

Dees, E. Claire ;

Sawyer, Lynda ;

Gatti, Lisa ;

Moore, Dominic T. ;

Collichio, Frances ;

Ollila, David W. ;

Sartor, Carolyn I. ;

Graham, Mark L. ;

Perou, Charles M. .

CLINICAL CANCER RESEARCH, 2007, 13 (08) :2329-2334

[9] Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy [J].

Chen, Yu-Hsiang ;

Hancock, Bradley A. ;

Solzak, Jeffrey P. ;

Brinza, Dumitru ;

Scafe, Charles ;

Miller, Kathy D. ;

Radovich, Milan .

NPJ BREAST CANCER, 2017, 3

[10] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

← 1 2 3 4 5 →